Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
Nymox Pharmaceutical Corporation (NYMXF) had Return on Equity of 45.94% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-4.28M |
|
-- |
|
-- |
|
$3.68M |
|
$-3.68M |
|
$-0.60M |
|
$-4.28M |
|
$-4.28M |
|
$-4.28M |
|
$-4.28M |
|
$-4.28M |
|
$-4.28M |
|
$-3.68M |
|
$-3.55M |
|
96.04M |
|
96.04M |
|
$-0.05 |
|
$-0.05 |
|
| Balance Sheet Financials | |
$0.57M |
|
$0.00M |
|
$0.00M |
|
$0.58M |
|
$9.88M |
|
-- |
|
-- |
|
$9.88M |
|
$-9.30M |
|
$-9.30M |
|
$-9.30M |
|
102.04M |
|
| Cash Flow Statement Financials | |
$-1.81M |
|
$-0.00M |
|
$1.74M |
|
$0.07M |
|
$0.01M |
|
$-0.07M |
|
$1.71M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.06 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-1.81M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Return on Equity |
45.94% |
45.94% |
|
-742.19% |
|
45.94% |
|
$-0.09 |
|
$-0.02 |
|
$-0.02 |
|